AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Axsome Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Product Sales | $633.80M | $381.68M | $202.46M | $50.04M | 99.3% | +66.1% |
| Royalty and Milestone Revenue | $4.70M | $4.02M | $2.41M | – | 0.7% | +17.0% |
| License Fee | – | – | $65.74M | – | – | – |
| Royalty [Member] | – | – | $2.41M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Axsome Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.